
Determination of Circulation Factors That Mediate the Health Benefits of Exercise in Mitochondrial AgingAward last edited on: 5/5/2023
Sponsored Program
STTRAwarding Agency
NIH : NIATotal Award Amount
$252,092Award Phase
1Solicitation Topic Code
866Principal Investigator
Tomas A ProllaCompany Information
Cytegen Corporation
4230 North Oakland Avenue Unit 154
Milwaukee, WI 53211
Milwaukee, WI 53211
(650) 473-0701 |
nfo@cytegen.com |
www.cytegen.com |
Research Institution
University of Wisconsin
Phase I
Contract Number: 1R41AG065131-01A1Start Date: 9/15/2020 Completed: 8/31/2021
Phase I year
2020Phase I Amount
$252,092Public Health Relevance Statement:
Narrative: Mitochondrial dysfunction is associated with a large number of diseases, including neuromuscular disorders, neurodegenerative disorders such as Parkinsons and Alzheimers diseases, and aging. Despite the central role of mitochondria in many diseases, few treatments are available, and none can stop disease progression. This application proposes to use novel and exciting findings on the role of exercise in inhibiting mitochondrial disease to develop novel therapeutic approaches.
Project Terms:
Affect; Age; age related; Aging; Alzheimer's Disease; Automobile Driving; base; Biochemical; Biological Assay; Blood Circulation; Cells; Complement; Data; Defect; Disease; Disease Progression; DNA biosynthesis; early onset; effective therapy; Endogenous Factors; endurance exercise; Engineering; Excision; Exercise; exercise training; Exonuclease; Fractionation; Functional disorder; Funding; Future; Genes; Genomics; Goals; Growth; Health Benefit; heart function; Hereditary Disease; Human; human disease; Impairment; improved; Individual; Injections; Knock-in; Laboratories; Lead; Longevity; Measurement; Mediating; Metabolic; Mitochondria; Mitochondrial Diseases; Mitochondrial DNA; mitochondrial dysfunction; mitochondrial fitness; Mitochondrial Proteins; Modeling; mouse model; Mus; Muscle; Muscle function; mutant; Mutant Strains Mice; Mutation; Myocardium; Nerve Degeneration; Neurodegenerative Disorders; Neuromuscular Diseases; normal aging; novel; novel therapeutic intervention; Parkinson Disease; Phase; phase II trial; Phenotype; Physiological; Plasma; Polymerase; preclinical study; premature; Premature aging syndrome; Preparation; Property; Proteins; Proteomics; Protocols documentation; research clinical testing; Resolution; Respiration; Role; Schedule; sedentary; Skeletal Muscle; small molecule; Syndrome; Testing; Tissues; Translating; Work
Phase II
Contract Number: ----------Start Date: 00/00/00 Completed: 00/00/00